Raymond James Financial
RARE icon

Raymond James Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

Raymond James Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$519K Buy
24,791
+4,940
+25% +$111K ﹤0.01% 4317
2025
Q4 		$457K Sell
19,851
-4,706
-19% -$155K ﹤0.01% 4330
2025
Q3 		$739K Sell
24,557
-5,875
-19% -$176K ﹤0.01% 3872
2025
Q2 		$1.11M Buy
30,432
+9,295
+44% +$335K ﹤0.01% 3509
2025
Q1 		$765K Sell
21,137
-637
-3% -$26.5K ﹤0.01% 3670
2024
Q4 		$916K Buy
+21,774
New +$1.08M ﹤0.01% 3508

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Raymond James Financial's RARE Position: Q1 2026 in Review

Raymond James Financial increased its Ultragenyx Pharmaceutical (RARE) stake by 25% in Q1 2026, buying an estimated $111K and bringing the position to 24,791 shares worth $519K. The position accounts for ﹤0.01% of the portfolio, ranked #4317.

Raymond James Financial first reported a position in RARE in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.11M in Q2 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Raymond James Financial held 24,791 shares of Ultragenyx Pharmaceutical worth $519K as of Q1 2026.
  • Raymond James Financial bought 4,940 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $111K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #4317 holding.
  • Raymond James Financial first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Ultragenyx Pharmaceutical position peaked at $1.11M in Q2 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.